Medicare’s 2017 340B proposal set drug pay from an estimated discount and put the proof on a claim modifier

On July 13, 2017, Medicare proposed paying 340B drugs at average sales price minus 22.5 percent, an outside estimate rather than its own survey. In our reading, that choice decided the policy’s legal fate, and the claims flag it required set its operating cost.

Looking Back revisits past weeks one at a time, up to the most recent, and asks what it meant for the banks, health systems and public agencies we serve. The series was written in 2026, with the benefit of hindsight, and each article says which week it looks back on.

Two-minute summaryThe dek and the first sentence of each section, quoted from the article

On July 13, 2017, Medicare proposed paying 340B drugs at average sales price minus 22.5 percent, an outside estimate rather than its own survey. In our reading, that choice decided the policy’s legal fate, and the claims flag it required set its operating cost.

  1. The week On July 13, 2017, the Centers for Medicare & Medicaid Services issued its proposed payment rule for hospital outpatient departments and ambulatory surgical centers for calendar year 2018, known as CMS-1678-P. [1] Its summary described updates to rates and quality programs and a request for information on flexibilities and efficiencies.
  2. The rate: an outside estimate standing in for a survey The proposed rate was a number borrowed from an advisory body.
  3. The flag: a modifier carried the policy onto each claim A drug price that depends on how the drug was bought needs a way to know how it was bought.
  4. The money: budget neutrality moved the savings to every hospital The third part is where the money went.
  5. The exits: who was outside the cut, and on what basis The fourth part is the boundary.
  6. How the policy reached different organizations The 340B cut was a Medicare outpatient policy, but its effects ran through several kinds of organizations, each with different exposure.
  7. Objections, in order Our reading of the 2018 policy has reasonable critics.
  8. What a hospital finance leader could check The 2018 policy and its aftermath offer a set of checks that apply to any payment rule that turns on a fact the claim does not naturally carry.
  9. With hindsight The hospital association and other parties challenged the 2018 and 2019 rates.

The week

On July 13, 2017, the Centers for Medicare & Medicaid Services issued its proposed payment rule for hospital outpatient departments and ambulatory surgical centers for calendar year 2018, known as CMS-1678-P. [1] Its summary described updates to rates and quality programs and a request for information on flexibilities and efficiencies. One proposal stood apart from the rest: a change in how Medicare paid hospitals for drugs bought through the 340B Drug Pricing Program. [1]

The 340B program, administered by the Health Resources and Services Administration, lets participating hospitals and other providers buy certain outpatient drugs from manufacturers at discounted prices. [2] Medicare’s hospital outpatient system paid every hospital the same rate for separately payable drugs, average sales price plus 6 percent, whatever the hospital had paid for them. [1] [2]

The proposal would change that for drugs bought with the discount. For 2018, CMS proposed to pay separately payable drugs, other than vaccines and drugs with pass-through status, at average sales price minus 22.5 percent when purchased through the 340B program. [1] Drugs not bought under the program would continue at average sales price plus 6 percent. [1]

The agency’s summary explained where the 22.5 percent figure came from. It was the Medicare Payment Advisory Commission’s estimate of the average minimum discount that eligible hospitals received for drugs acquired under the 340B program. [1] CMS was not proposing a figure from its own survey of what hospitals paid; the proposed rule said it had no hospital acquisition cost data for 340B drugs. It was adopting an outside estimate of the average minimum discount. [1] [2]

The agency framed the change around patients’ costs. It said it was responding to recent trends of increasing drug prices, some of whose cost falls on Medicare beneficiaries. It invited comment on how to implement the proposal so as to bring down out-of-pocket drug costs while letting providers meet patients’ needs. [1]

The summary also recalled history. In its final payment rule for 2009, the agency had asked for comments on whether it should adopt a separate payment method for participating 340B hospitals, and whether any classes of drugs should be excepted. [1] The July 2017 proposal answered that old question.

The rest of the package set the frame for the drug proposal. The agency proposed to raise these hospital rates by 1.75 percent for 2018. That figure reflected a projected hospital market basket increase of 2.9 percent, reduced by a 0.4 percentage point productivity adjustment and a 0.75 percentage point adjustment required by law. [1] CMS estimated an overall 2.0 percent payment increase for hospitals, counting all proposals except the 340B change. [1]

That exclusion is a detail worth noticing. The headline estimate of what hospitals would gain left out the one proposal that would move money between them. The summary did not say, in that paragraph, how the 340B change would be handled in the totals. [1]

The same rule carried other proposals that touched hospital operations. CMS proposed to reinstate, for 2018 and 2019, non-enforcement of the direct supervision requirement for certain therapeutic services at critical access hospitals and small rural hospitals with 100 or fewer beds. [1] It proposed to remove total knee arthroplasty from the inpatient-only list, and to remove six measures from the related quality reporting program. [1]

Comments on the proposed rule and the request for information were due by September 11, 2017. [1] The summary pointed readers to the Federal Register’s public inspection page for the full text, where the detail of how the change would work on a claim would appear. [1]

A payment rule is a set of prices. It is also a set of instructions about evidence: what a hospital must show, on which record, to be paid a given amount. The 2018 340B proposal can be read as a price cut. We think it is better understood as a decision about evidence, made before the evidence existed. [1] [2]

Our argument is that CMS set a group-specific drug price from an outside estimate, without its own survey of acquisition costs. It then had to build a claims flag to identify which drugs the price applied to. Both choices, the missing survey and the new flag, shaped what happened next. [2] [3] [4] We take the policy in four parts:

  1. The rate: where ASP minus 22.5 percent came from, and what legal footing CMS chose.
  2. The flag: how a claim would show that a drug was bought at a 340B discount.
  3. The money: where the savings went under budget neutrality, and who paid.
  4. The exits: which hospitals and drugs were outside the cut, and why.

The first part is the price. The second is the record that triggers the price. The third is the arithmetic that spreads the effect across all hospitals. The fourth is the boundary. Together they cover the policy from the number to the people it reached. After the four parts, we look at how the policy reached different organizations, answer objections, and list what a hospital finance leader could check.

A note on sources and our reading. We describe the July 2017 proposal from CMS’s fact sheet and the proposed rule text. We describe what followed from the final rule, the Supreme Court’s decision and later CMS rules. Statements about what the statute permitted are ours or the Court’s, and we say which. Hospitals should confirm their own billing and payment questions with counsel and their Medicare contractor.

The rate: an outside estimate standing in for a survey

The proposed rate was a number borrowed from an advisory body. The proposed rule set out the chain of reports behind it. [2]

Three estimates, one choice

The proposed rule cited three sources on the size of 340B discounts. The Medicare Payment Advisory Commission, in its May 2015 report, estimated that 340B hospitals received a minimum discount of 22.5 percent of average sales price for drugs paid under the outpatient system. [2]

The rule also cited the commission’s March 2016 report of an HHS Office of Inspector General estimate that discounts across all 340B providers averaged 33.6 percent of average sales price. And it cited a Government Accountability Office finding that 340B discounts ranged from an estimated 20 to 50 percent. [2]

CMS chose the lowest of these framings, the commission’s minimum. Citing the commission, the rule said the estimate was conservative and that the actual average discount was likely much higher than 22.5 percent. [2] Choosing the floor meant that, on CMS’s own account, the cut would understate the typical discount rather than overstate it.

The rule gave a reason for using an average at all. Ceiling prices under the 340B program are confidential, so CMS said it could not set drug-by-drug rates without revealing them. [2] An average discount, applied to every covered drug, protected that confidentiality while moving payment toward cost.

How the commission had built its number

The proposed rule summarized the commission’s method. It used the formula for the 340B ceiling price, average manufacturer price minus the unit rebate amount. Lacking manufacturer price data, it used each drug’s average sales price as a proxy. [2]

The rule noted the commission’s own caveat that its ceiling price estimates were conservative and likely higher, possibly much higher, than actual ceiling prices. [2] It also noted that participation in the program’s prime vendor arrangement often yields prices about 10 percent below the ceiling, and said the average discount was likely higher for that reason, among others. [2]

In our reading, the chain shows an agency aware that its number was an estimate built on proxies. That awareness is to CMS’s credit as analysis. It also shows how far the rate was from a measured acquisition cost.

Discounts below the ceiling

The proposed rule added a detail that pushed the real discount further from the borrowed number. It described the program’s prime vendor arrangement, through which participating entities can buy below the 340B ceiling price. [2]

Citing an HRSA budget document, the rule said that by the end of fiscal year 2014 the arrangement offered nearly 7,000 products below the ceiling price. They included 3,557 covered outpatient drugs, with estimated average savings of 10 percent below the ceiling. [2] A hospital using those prices would hold a discount larger than the ceiling-based estimate assumed. [2]

For a hospital pharmacy leader, this meant the gap between the new Medicare rate and actual cost would vary widely by hospital. It depended on how much of the hospital’s 340B buying went through the prime vendor and at what prices. One average rate would fit few hospitals exactly.

The statute gave CMS two routes for setting these drug rates. The proposed rule invoked one of them. It said that where hospital acquisition cost data are not available, the payment is the average price for the drug, as calculated and adjusted by the Secretary as necessary. [2]

CMS said it did not have hospital acquisition cost data for 340B drugs. It therefore proposed to use that average-price authority and to adjust the result by 22.5 percent below average sales price for drugs acquired under the program. [2] The adjustment applied only to drugs bought by 340B hospitals through the program. Other hospitals, and other drugs, kept the existing rate. [2]

The other route, which CMS did not take, rested on a survey of hospitals’ acquisition costs for each covered drug. The Supreme Court later described that route as the one that allows rates to vary by hospital group. [4] In July 2017, the proposal did not discuss why CMS was not surveying. It stated that the data were not available. It did ask for comment on a longer-term option: requiring 340B hospitals to report their acquisition cost for each drug on the Medicare claim. [2]

Why there was no survey

The Supreme Court later recorded the history. For more than a decade after the provisions took effect in 2006, HHS had not surveyed hospitals’ acquisition costs. It attempted such a survey only once, in 2020, after the litigation began. [4]

At oral argument, the government explained the reluctance in terms of burden on the agency and on hospitals, and doubts about accuracy, as the Court summarized. [4] Those are real costs. A survey asks every hospital to report what it paid for each covered drug, a task that touches purchasing systems, contracts and rebate records. [4]

The statute anticipates that work. The Court described a separate provision that sets out the requirements for acquisition cost surveys in detail. [4] In the Court’s account, the survey lets the agency see whether hospitals’ costs differ in a meaningful, statistically significant way before it treats groups differently. [4]

In our reading, the 2017 proposal replaced that measured step with an outside estimate. The estimate was transparent and conservative. It was not the data the statute named as the basis for treating one group of hospitals differently from another. [2] [4]

Why the footing mattered to finance teams

A finance leader reading the proposal in July 2017 faced a planning question. A rate set by adjustment under the average-price authority could be challenged on whether that authority stretched to a group-specific cut. A rate set from a survey would have rested on the route the statute described for varying rates. [2] [4]

We do not claim that this risk was obvious to everyone at the time. We note only that the legal footing was stated in the rule itself, and that it later decided the outcome. [2] [4] A budget that treated the cut as permanent was betting on one reading of a contested statute.

The flag: a modifier carried the policy onto each claim

A drug price that depends on how the drug was bought needs a way to know how it was bought. Medicare claims did not carry that fact. The proposed rule said so plainly. [2]

The data gap CMS named

The proposed rule stated that current data limitations inhibited identification of which drugs were acquired under the 340B program in Medicare outpatient claims. That gap, it said, had limited both researchers’ and CMS’s ability to analyze the difference in acquisition cost between 340B and other drugs. [2]

This is the same gap that kept CMS from a survey-based rate. The program could see what it paid for each drug. It could not see what the hospital paid, or whether the purchase used the discount. [2]

The first design: presume the discount

The proposed rule announced an intent to establish a modifier, effective January 1, 2018, for hospitals to report with separately payable drugs that were not acquired under the 340B program. [2] Because a large share of outpatient hospitals participated in the program, CMS said it was appropriate to presume a drug was bought under 340B unless the hospital said otherwise. [2]

In this design, the default was the lower price. A hospital that bought some drugs outside the program had to flag each of those claim lines to be paid the higher rate. The burden of proof sat with the hospital, line by line, for every non-340B drug. [2]

The rule also flagged a complication. It said CMS would provide guidance on billing for patients covered by both Medicare and Medicaid, for whom covered entities do not receive a discount under the program. [2] That note shows CMS anticipated that the same drug, in the same hospital, could carry different purchase histories by patient.

The reversal in the final rule

The final rule, published November 13, 2017, kept the rate and reversed the flag. [3] CMS said it had considered the administrative and financial challenges of the proposed approach and, to reduce burden, would instead require a modifier on drugs that were acquired under the program. [3]

Beginning January 1, 2018, hospitals subject to the cut would report modifier JG on the same claim line as a 340B-acquired drug. Applying JG to a separately payable drug would trigger payment at average sales price minus 22.5 percent. [3] Drugs bought outside the program would carry no modifier and keep the higher rate. [3]

CMS gave two reasons. The JG approach aligned with modifier requirements several state Medicaid programs already imposed. And flagging 340B purchases, rather than other purchases, would help guard against duplicate discounts, where a drug draws both a 340B discount and a Medicaid rebate. [3]

What the flag demanded of hospital systems

In our reading, the flag moved the policy from the rate table into the hospital’s pharmacy and revenue cycle systems. A hospital had to know, for each administered dose, whether the drug came from 340B inventory. That fact lives in purchasing and inventory records, not in the clinical record. [3]

A hospital that keeps a single physical inventory and decides 340B eligibility afterward would face a timing problem. The claim may be built before the accounting decides which purchase the dose came from. The final rule did not prescribe how hospitals should resolve this. It required the modifier and left the method to them. [3]

CMS also answered complaints about lead time. It said hospitals had been on notice since the proposed rule went on display at the Office of the Federal Register on July 13, 2017 that it intended to establish a modifier. [3] That was a statement about notice. It was not a statement that the systems work was simple.

Patients covered by both programs

The proposed rule’s note about dual-eligible patients deserves a closer look. It said covered entities do not receive a 340B discount for drugs given to these patients, and promised guidance on billing for them. [2] The final rule returned to the point. It said state Medicaid programs should be aware of JG to help prevent inappropriate billing of manufacturer rebates for those patients. [3]

Medicare and Medicaid both pay for some patients. When Medicaid pays, a manufacturer rebate may be owed. When the drug was bought at a 340B price, the rebate should not also be claimed. The modifier gave state programs a way to see which Medicare claim lines involved 340B drugs. [3]

For a hospital, the dual-eligible case is where errors compound. A wrong flag affects the Medicare payment, the state’s rebate claim and the hospital’s 340B program records at once. In our reading, a test plan for the modifier should start with these patients, because the cost of an error is highest there.

The flag as evidence

Once in place, the JG modifier became a record. Every flagged line documented that the hospital bought that drug under the 340B program. That record served the payment cut, the Medicaid duplicate-discount check and, later, any calculation that depended on knowing which units were 340B units. [3] [7]

A record created to apply a price is also evidence for audits. A hospital that applied JG inconsistently would have paid claims at the wrong rate and created an inaccurate history of its own purchasing. In our reading, that made the modifier a compliance control as well as a billing code.

An auditor sampling these claims would ask a simple question of each flagged line: show the purchase record. A hospital able to tie each JG line to a 340B purchase, and each unflagged line to a non-340B purchase, has a defensible record. A hospital that cannot has a payment error waiting to be found. [3]

The flag also mattered for what CMS could learn. With JG in place, Medicare claims would show 340B drugs for the first time. The data gap the proposed rule described would begin to close, though only for what hospitals reported. [2] [3]

The money: budget neutrality moved the savings to every hospital

The third part is where the money went. The outpatient payment system is budget neutral by statute in key respects. A cut in one place has to be matched by an increase somewhere else within the system. [2] [3]

The proposed treatment

The proposed rule said the reduced 340B drug payments would be included in the budget neutrality adjustments, and that the budget neutral weight scalar would not apply in setting these drug payments. [2] It invited comment on whether to apply some or all of the savings to particular services, or to Part B generally, instead of simply raising the conversion factor. [2]

Reading the July headline

The July fact sheet estimated a 2.0 percent overall payment increase for hospitals under the outpatient system, counting every proposal except the 340B change. [1] A board reading that figure would have seen growth. A 340B hospital’s own result could be very different, because the excluded proposal was the one aimed at it. [1]

In our reading, the exclusion was reasonable as presentation, since the budget neutral treatment was still open for comment. It also meant the headline number told each hospital little about its own position. Finance teams had to rebuild the estimate from their own drug and service mix. [1] [2]

The final treatment and its size

The final rule chose the conversion factor. CMS estimated that the cut would reduce drug payments by $1.6 billion, and said that amount would be redistributed in an equal offsetting amount to all hospitals paid under the outpatient system. [3] The redistribution raised the conversion factor for all non-drug items and services by 3.2 percent. The $1.6 billion estimate was up from $900 million in the proposed rule. 340B hospitals lost on drugs and gained some of it back on services. [3]

In our reading, this redistribution changed the politics and the accounting of the cut. A hospital outside the 340B program gained from the policy without changing anything it did. A 340B hospital’s net effect depended on its mix of drugs and other services. [3]

A system with mixed hospitals

Consider a hypothetical health system with three hospitals: one 340B hospital subject to the cut, one children’s hospital and one hospital outside the program. Under the final rule, the first loses on drugs and gains a little on services. [3] The second keeps its drug rate and gains on services. The third gains on services alone. [3]

The system’s net position depends on the balance across the three. In our reading, a system-level budget that netted the effects could look stable while the 340B hospital absorbed the loss. That is an internal allocation question the payment rule did not answer. [3]

Where patients came in

CMS’s stated aim was lower costs for beneficiaries. The proposed rule pointed out that patients pay a copayment equal to 20 percent of the outpatient payment rate, so a lower drug rate meant a lower copayment on that drug. [2] It cited an Inspector General finding that, for some drugs in 2013, the patient’s coinsurance alone exceeded what the covered entity paid for the drug. [2]

Budget neutrality worked the other way on services. A higher conversion factor raised payment, and so copayments, for non-drug services. The later remedy rule noted this link between the conversion factor and patients’ cost-sharing. [5] The net effect on any one patient depended on what care that patient received.

The money that would have to come back

Budget neutrality had a consequence nobody needed in 2018. If the cut were ever undone for past years, the extra money paid for non-drug services would also be in question. The remedy rule of 2023 confronted exactly this, as we discuss in the hindsight section. [5] In our reading, a finance team in 2017 had two exposures, not one: the drug cut and the service increase that paid for it.

The exits: who was outside the cut, and on what basis

The fourth part is the boundary. Every group-specific rate needs an edge. The 2018 policy drew several, some in the proposal and more in the final rule. [2] [3]

Drugs outside the cut

The proposal excluded two kinds of drugs from the lower rate. Drugs on pass-through status are required to be paid on the average sales price method. Vaccines are excluded from the 340B program altogether. [2] The proposal invited comment on whether other types, such as blood clotting factors, should also be excluded. [2]

The policy also reached only separately payable drugs. Drugs packaged into the payment for a procedure had no separate rate to cut. The final rule said hospitals could report JG or TB on packaged drugs, but that doing so would not change payment. [3]

Biosimilars at the edge

The final rule also settled how the cut applied to biosimilar biological products, which some commenters had addressed. Biosimilars not on pass-through status and bought through the program or its prime vendor would be paid at average sales price minus 22.5 percent of the reference product’s average sales price. [3] Biosimilars on pass-through status kept average sales price plus 6 percent of the reference product. [3]

This is a small rule with a large lesson about edges. Each class of product needed its own answer, and the answer depended on another product’s price. The later remedy rule noted that CMS changed the biosimilar basis for 2019, paying on the biosimilar’s own average sales price instead. [5]

Hospitals outside the system

Critical access hospitals are paid on a cost basis outside the outpatient prospective system, so the cut did not reach them. The proposed rule noted they are paid at 101 percent of reasonable costs by statute. [2] The final rule listed hospitals excluded from the system, such as critical access hospitals and those paid under the Maryland waiver, as outside the modifier requirement. [3]

Hospitals exempted by the final rule

The final rule added a further set. Rural sole community hospitals, children’s hospitals and cancer hospitals exempt from the prospective system would not be subject to the reduced rate for 2018. [3] They would report informational modifier TB on 340B drugs instead, for tracking, and continue to be paid average sales price plus 6 percent. [3]

The final rule explained that children’s and cancer hospitals would also receive higher payment for non-drug services through the redistributed conversion factor. [3] In our reading, these hospitals gained twice: no drug cut, and a share of the redistribution. CMS said it might revisit the exemptions in later rulemaking. [3]

Why the exits mattered to the argument

Each exit required its own identification on the claim. The TB modifier, the hospital type, the pass-through status and the drug’s separate payability all fed the final price. A policy that began as one percentage became a decision tree applied to every drug line. [3]

That tree reinforces our main point. Without a survey, CMS could not set prices from measured costs by group. It could only set a group rate from an estimate and then rely on hospitals to sort their own claims into the right branch. [2] [3] [4]

How the policy reached different organizations

The 340B cut was a Medicare outpatient policy, but its effects ran through several kinds of organizations, each with different exposure.

340B hospitals subject to the cut

These hospitals bore the direct reduction on separately payable 340B drugs, offset partly by higher service rates. [3] Their operational task was the modifier: getting JG onto every 340B drug line from January 1, 2018. Their financial task was modeling a net effect that depended on their own case mix.

Exempted hospitals

Rural sole community hospitals, children’s hospitals and the exempt cancer hospitals kept the higher drug rate and still had to report TB. [3] Their systems work was similar to that of hospitals subject to the cut, but the payment stakes of an error were different. A missing TB modifier would not change their payment, but it would leave CMS’s tracking data incomplete. [3]

Hospitals outside the 340B program

Non-340B hospitals received the redistributed money through the conversion factor without any new reporting. Their exposure arose later. If the policy were reversed with a budget neutral remedy, the extra service payments they had received would be part of the calculation. [3] [5]

For these hospitals, the later remedy carried a twist. The 2023 rule’s recovery of extra service payments excluded hospitals that enrolled in Medicare after January 1, 2018, but reached those that had been paid throughout. [5] A hospital that never touched a 340B drug could still see its service rates reduced to repay a policy it had no part in.

Critical access hospitals

Paid on reasonable cost outside the prospective system, critical access hospitals were outside both the cut and the redistribution. [2] [3] For a rural health network that operates both critical access hospitals and prospective-system hospitals, that meant two payment regimes for the same drug in the same network.

Health systems with off-campus departments

The 2018 rule did not apply the cut to every setting at first. CMS’s later account says that for 2019 it extended the 340B rate to drugs furnished in certain off-campus departments paid under the physician fee schedule. [5] For an ambulatory network expanding off-campus infusion sites, the policy boundary moved with the calendar. Site planning had to track the payment rule year by year.

State Medicaid programs

CMS said state Medicaid programs should be aware of the JG modifier, to help prevent inappropriate billing of manufacturer rebates for patients covered by both programs. [3] In our reading, a Medicare billing code thus became an input to state rebate integrity work, which the state had to choose to use.

Patients

Beneficiaries were the stated beneficiaries of the cut. A patient receiving a separately payable 340B drug at a hospital subject to the policy would owe 20 percent of a lower rate. [2] [3] A patient receiving other outpatient services anywhere in the system would owe 20 percent of a slightly higher rate, because of the redistribution. [3] [5] The policy changed who paid what, as well as how much hospitals received.

Revenue cycle and pharmacy vendors

The organizations that build charge masters, pharmacy inventory systems and claim scrubbers had to support the new modifiers. CMS did not regulate those vendors. But a hospital’s compliance depended on how their systems decided which doses were 340B doses. [3] Contracts and testing for that logic became part of the hospital’s control environment.

Boards and audit committees

Hospital boards approve budgets that rest on payment assumptions. The 2018 policy put a contested legal reading inside one of those assumptions from the start. [2] [4] An audit committee could reasonably have asked management three things: what the cut was worth, what the redistribution was worth, and what would happen to each if a court disagreed with CMS. The answers would have framed the hospital’s finances through the litigation and the remedy that followed.

Objections, in order

Our reading of the 2018 policy has reasonable critics. We take the strongest objections in turn.

1. The cut was about drug prices and patients, not evidence

CMS’s stated purpose was to lower beneficiaries’ costs and align payment with acquisition cost. [1] [2] We accept that purpose. Our point is that the means chosen, an estimated group rate and a claims flag, determined the legal and operational outcome regardless of purpose.

2. A survey was impractical in 2017

CMS said acquisition cost data were not available, and ceiling prices were confidential. [2] Those were real constraints. But the statute described a survey route, and CMS later ran one. [4] [7] The constraint was one of time and effort, not impossibility.

3. The commission’s estimate was conservative, so hospitals were not harmed

On CMS’s account, the 22.5 percent floor understated the average discount. [2] That supports the policy as economics. It does not answer the legal question the Supreme Court decided, which turned on the survey, not on whether the estimate was fair. [4]

4. The modifier was a routine billing change

Modifiers are common in Medicare billing. This one, though, carried a payment consequence of 28.5 percentage points of average sales price on every flagged line, the gap between plus 6 and minus 22.5 percent. [3] In our reading, a code with that weight is a financial control and should be treated as one.

5. Budget neutrality made the policy harmless overall

Budget neutrality kept total outpatient spending level within the system. [3] It did not keep any single hospital level, and it created the second exposure we described: service payments that might later have to be recovered. [5]

6. The Court’s ruling turned on statutory text, not on evidence

That is fair. The Court decided a question of statutory interpretation. [4] But the text it read was about evidence. It made a survey the precondition for treating hospital groups differently. A ruling about the required evidence is still a ruling about evidence. [4]

What a hospital finance leader could check

The 2018 policy and its aftermath offer a set of checks that apply to any payment rule that turns on a fact the claim does not naturally carry.

  1. For each payment adjustment, record which statutory authority the agency invoked, and whether a challenge to that authority is pending.
  2. Map where the fact that triggers the payment lives in your systems: purchasing, inventory, clinical or billing.
  3. Test the claim logic that applies the modifier against purchasing records, on a sample, before and after go-live.
  4. Model both sides of a budget neutral change: the cut and the redistribution, since either may be revisited.
  5. Keep exempt-status evidence current, since an exemption can be narrowed or removed in later rulemaking.
  6. Treat any reversal or remedy as a two-way calculation that may reach payments you received as well as those you lost.

The second and third checks are where the 2018 policy made its heaviest demand. A rule can change a rate overnight. A hospital’s ability to prove which rate applies to which dose depends on purchasing, inventory and billing systems that change slowly. [3] A finance leader who cannot show that link on a sample of claims does not yet know the hospital’s exposure.

The fourth check draws on the remedy rule. A budget neutral cut made money flow two ways, and the reversal made it flow back two ways. [5] The fifth reflects that exemptions are policy choices CMS has said it may revisit. [3] [7]

The first and last checks address the legal risk that the 2018 policy carried from its first day. The middle checks address the record the policy relied on. None of them requires predicting a court’s ruling. They require knowing where the money and the evidence sit before an agency or a court asks.

With hindsight

CMS finalized the cut largely as proposed on November 13, 2017, with the reversed modifier design and the added exemptions. [3] It continued the policy in later years and, from 2019, extended it to certain off-campus departments, according to its later account. [5]

The hospital association and other parties challenged the 2018 and 2019 rates. On June 15, 2022, a unanimous Supreme Court held the rates unlawful. [4] The Court read the statute as giving HHS two options. With a survey of acquisition costs, HHS may set rates by average acquisition cost and vary them by hospital group. Without a survey, it must use average price and may not vary rates by group. [4]

The Court noted that from 2006 until 2018 HHS had not surveyed, had set rates at about 106 percent of average sales price, and had not varied them by group. [4] Because HHS did not survey for 2018 or 2019, it could not lawfully cut rates only for 340B hospitals. The Court remarked that whether 340B payments were meant to help hospitals serving low-income and rural communities was a policy debate it would not resolve. [4]

The remedy came by rule. On November 8, 2023, CMS published a final rule paying affected 340B hospitals lump sums. Each sum was the difference between what a hospital received and what it would have received without the cut, from 2018 through September 27, 2022. [5] CMS estimated the remaining amount at $9.004 billion, which it rounded to $9.0 billion. [5]

The same rule addressed the other side of budget neutrality. CMS estimated that the policy had produced $7.8 billion in extra payments for non-drug services. It finalized an annual 0.5 percent reduction to the outpatient conversion factor for non-drug services to recover that amount, beginning in 2026. [5] Hospitals that enrolled in Medicare after January 1, 2018 were excluded from the reduction. [5]

For 2026, CMS kept the reduction at 0.5 percent after considering a proposal for 2 percent. [6] It also announced that it would survey the acquisition costs of separately payable drugs at all outpatient hospitals, with a submission window opening by early 2026. It tied the survey to section 5 of Executive Order 14273 of April 18, 2025, which directed HHS to plan such a survey. [6]

The survey ran from January 1 through April 7, 2026. [7] In its final rule for 2027, published November 6, 2026, CMS had proposed paying 340B-acquired drugs at average sales price minus 33.4 percent, the discount it said the survey showed. After taking the survey into account, it finalized its alternative instead: average sales price minus 28 percent, calculated from 340B ceiling price data. [7] It raised the annual remedy offset from 0.5 percent to 2 percent for 2027, rather than the 3 percent it had proposed. [7]

The 2027 rule kept exemptions for rural sole community hospitals, children’s hospitals and the exempt cancer hospitals. [7] It kept JG for 340B-acquired drugs and TB for informational reporting. It also finalized a new modifier, ND, which all hospitals paid under the outpatient system must report from January 1, 2027, on separately payable drugs not acquired through the 340B program. [7] In effect, hospitals will then flag both kinds of purchase. The 2017 proposal’s idea of flagging non-340B drugs returned, alongside the final rule’s flag on 340B drugs. [2] [3] [7]

What held up? CMS’s economic premise held in one sense. Its own survey found a deeper average discount than the 22.5 percent floor it had borrowed in 2017. [2] [7] What did not hold was the legal footing. The Supreme Court found that a group-specific rate required the survey CMS had not done. [4]

The cost of skipping the survey was large. Affected hospitals were repaid through the 2023 remedy rule. All outpatient hospitals then faced a multiyear reduction to recover the redistributed money. [5] [6] [7] In our reading, the policy’s original weakness was the one visible in July 2017: a group rate built on an estimate, enforced through a flag the claims system did not yet have. [2]

The 2027 rule also reported the survey’s response rate, which CMS put at 29.8 percent of all eligible hospitals and 41.4 percent of a refined population. [7] Commenters questioned whether that was enough. In our reading, the new rate’s legal durability may turn partly on that debate, as the 2018 rate turned on the absence of a survey.

Spotted an error? Tell us and we will check it and correct the article where needed.

  • 340B
  • Medicare
  • outpatient payment
  • revenue cycle
  • budget neutrality